Refractory ulcerative colitis treatment

Gastroenterology and Hepatology

Volumn 3, Issue 1, 2007, Pages 64-69

  MacDermott, Richard P ^a,b   Green, Jesse A ^a,c  

^a Department of Medicine ^*  (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c Inflammatory Bowel Disease Center   (United States)

Author keywords

5 ASA; 6 MP; Azathioprine; Corticosteroids; Cyclosporine; Infliximab; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; TIOGUANINE;

ABSCESS; ANAPHYLAXIS; ASPERGILLOSIS; BLOODY DIARRHEA; CANDIDIASIS; CHRONIC DISEASE; COCCIDIOIDOMYCOSIS; DISEASE SEVERITY; DRUG EFFICACY; HISTOPLASMOSIS; HUMAN; HYPERTENSION; INFECTION COMPLICATION; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PERITONITIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; REVIEW; SEIZURE; SEPSIS; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

EID: 33846920632     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Vega R, Bertran X, Menacho M, et al. Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol. 1999;94:1053-1056.
2. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
3. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl) 5:V1-16.
4. Regueiro M, Loftus EV, Steinhart AH, et al. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctiris: summary statement. Inflamm Bowel Dis. 2006;12:972-978.
5. Regueiro M, Loftus EV, Steinhart AH, et al. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctiris: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979-994.
6. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867-1871.
7. Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol. 2002;97:2939-2941.
8. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955;4956:1590-1593.
9. Angus P, Snook JA, Reid M, et al. Oral fluticasone proprionate in active distal ulcerative colitis. Gut. 1992;33:711-714.
10. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on a controlled therapeutic trial. Br Med J. 1974;4:627-630.
11. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990;85:717-722.
12. George J, Present DH, Pou R, et. al. The long-term outcome of ulcerative colitis treated with 6- mercaptopurine. Am J Gastroenterol. 1996,91:1711-1714.
13. Ardizzone S, Molteni F, Imbesi V, et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol. 1997;25:330-333.
14. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J. 1992;305:20-22.
15. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol. 1996;91:423-433.
16. Cuffari C, Present DH, Bayless TM, et al. Optimizing therapy in patients with pancolitis. Inflamm Bowel Dis. 2005;11:937-946.
17. Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
18. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731-743.
19. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20:1149-1157.
20. Sands BE, Tremaine WJ, Sandborn WJ, et. al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83-88.
21. Chey WY, Hussain A, Ryan C, et. al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol. 2001;96:2373-2381.
22. Su C, Salzberg BA, Lewis JD, et. al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol. 2002;97:2577-2584.
23. Rutgeerts P, Sandborn WJ, Feagan BG, et. al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462-2476.
24. Remicade (infliximab) for IV injection. Package Insert. Centocor, Malvern, Pennsylvania, USA, 2006; Revised May 2006.
25. Orenstein R, Matteson EL. TNF Inhibitors and Infections. Infect Med. 2006;23:99-114.
26. Aberra FN, Lichtenstein GR. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:685-695.
27. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 1985;89:1005-1013.
28. Meyers S, Lerer PK, Feuer EJ, et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective randomized, double-blind clinical trial. J Clin Gastroenterol. 1987;9:50-54.
29. Lichtiger S, Present DH, Kornbluth A, et. al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330:1841-1845.
30. Kornbluth A, Present DH, Lichtiger S, et. al. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol. 1997;92:1424-1428.
31. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five year experience. Am J Gastroenterol. 1999;94:1587-1592.
32. Loftus CG, Loftus EV Jr, Sandborn WJ. Cyclosporin for refractory ulcerative colitis. Gut. 2003;52:172-173.
33. Van Assche G, D'Heans G, Noman M, et. al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025-1031.
34. Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe uclerative colitis. Am J Gastroenterol. 1996;91:2498-2499.
35. Jarnerot G, Hertervig E, Friis-Liby I, et. al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811.
36. Becker JM. Indications for colectomy and choice of procedures. In Advanced Therapy of Inflammatory Bowel Disease. Eds. Bayless TM, Hanauer SB. B.C. Decker Inc, Hamilton/London 2001:175-178.
37. Pemberton JH, Kelly KA, Beart RW Jr, et. al. Ileal pouch-anal anastamosis for chronic ulcerative colitis. Long-term results. Ann Surg. 1987;206:504-513.
38. Meagher AP, Farouk R, Dozois RR, et. al. J ileal pouch-anal anastamosis for chronic ulcerative colitis: complications and long term outcome in 1310 patients. Br J Surg. 1998;85:800-803.
39. Fazio VW, Ziv Y, Church JM, et. al. Ileal pouch-anal anastamoses complications and function in 1005 patients. Ann Surg 1995;222:120-127.
40. Pemberton JH. The problem with pouchitis. Gastroenterology. 1993;104:1209-1211.